Product Name: CDK1-3 Selectide
Product Number: PE-01BGO99
Size: 200 µg      Price:33.00
1 mg      $US65.00
5 mg      143.00
Peptide Name: CDK1-3 Selectide

Product Use: For assaying the phosphotransferase activity of Cyclin-dependent protein-serine kinase 1; Cell division control protein 2 homologue (UniProt ID P06493).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: GTPVKKRA

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1030.3 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: CDK1-3

Scientific Background: CDK1 (CDC2) is a protein-serine/threonine kinase of the CMGC group and CDK family. It plays an essential role in cell cycle control in eukaryotic cells by regulating the centrosome cycle, mitotic onset, G2-M phase transition, G1 progression, and G1-S phase transition through an association with various interphase cyclin proteins. Phosphorylation events at T14 or Y15 on the protein are inactivating, while phosphorylation at T161 is stimulatory. CDK1 appears to be a tumour requiring protein (TRP). Gain-of-function mutations in the CDK1 gene have been linked to several forms of cancer, indicating an oncogenic role for the CDK1 protein. Cells transformed with the oncogene MYC undergo apoptosis when treated with small-molecule CDK1 inhibitors. Elevated expression of CDK1 has been reported as a diagnostic marker for cancer progression in esophageal adenocarcinoma, potentially reflecting the role of the CDK1 protein in tumourigenesis. CDK1 expression can be used as a prognostic indicator for early breast cancer. For example, breast cancer tumours with high expression of CDK1 are correlated with a significantly lower 5-year patient survival rate (66. 9%) than tumours that have low levels of CDK1 expression (84. 2%).